Clinical trials: Post-menopausal Women
Postmenopausal Osteoporosis
A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
This study is structured to estimate the effect of denosumab, compared to placebo and alendronate, on several bone parameters.
- Trial name
- NCT00293813
- Testing
- Alendronate, Denosumab
- Volunteers
- 247 people
- Sponsor
- Amgen
Hot Flashes
Hypnosis For Hot Flashes Among Postmenopausal Women in a Randomized Clinical Trial
This study is designed to determine the effect of a Hypnosis Intervention on reducing hot flash frequency (perceived impact vs. physiologically measured impact), severity and daily interference in post-menopausal women.
- Trial name
- NCT01293695
- Testing
- Hypnosis, Structured attention
- Where
- United States
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Baylor University
Post Menopausal Breast Cancer
Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
This international, multi-center, open-label, single-arm study evaluated the safety and tolerability profile of everolimus in post-menopausal women with HR positive, HER2 negative locally advanced or metastatic breast cancer…
- Trial name
- EVEREXES (NCT03176238)
- Testing
- everolimus, exemestane
- Where
- 55 sites in Australia, India and 11 more
- Volunteers
- 235 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
The purpose of this study is to microscopically examine breast cancer cells of pre-menopausal and post-menopausal women before and after exposure to one of the two commonly used breast cancer drugs, tamoxifen or fulvestrant.
- Trial name
- NCT02936206
- Testing
- Fulvestrant, Tamoxifen
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Breast Cancer, DCIS
CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)
This study will prospectively evaluate the technical feasibility, acute toxicity, late effects and oncologic outcomes of CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI) in early stage breast cancer.
- Conditions
- Breast Cancer, DCIS, Invasive Ductal Carcinoma
- Trial name
- CK-SAPBI (NCT02365714)
- Testing
- CK Stereotactic Accelerated Partial Breast Irradiation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Georgetown University
Post-Menopausal Osteoporosis
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
This 2-arm study was designed to assess the long-term safety and tolerability of intravenous (IV) treatment with 2 mg or 3 mg Bonviva in women with post-menopausal osteoporosis who had previously completed Bonviva study BM16550…
- Trial name
- NCT00551174
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 39 sites in United States, Australia and 13 more
- Volunteers
- 781 people
- Sponsor
- Hoffmann-La Roche
Bone Loss, Post Menopausal Osteoporosis
Lactobacillus Acidophilus and Postmenopausal Women
This study aims to evaluate the effect of Lactobacillus acidophilus supplementation on calcium status and bone densitometry in postmenopausal women in a randomized, double-blind placebo-controlled study.
- Conditions
- Bone Loss, Post Menopausal Osteoporosis, Mineralization
- Trial name
- LaBon (NCT05332626)
- Testing
- Probiotic group
- Where
- Poland
- Volunteers
- 90 people
- Sponsor
- Poznan University of Life Sciences
Breast Cancer
Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00611715
- Testing
- erlotinib hydrochloride, letrozole, fluorescence in situ hybridization
- Where
- 9 sites in United States
- Volunteers
- 48 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer
Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer
To test whether the addition of the COX-2 inhibitor, celecoxib, will decrease the gene expression of CYP19 in breast cancers collected from postmenopausal women that receive neoadjuvant exemestane.
- Trial name
- NCT00201773
- Testing
- Exemestane, Celecoxib, Correlative studies
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
This is a two-arm, randomized, double-blind, multicenter, pre-operative study to evaluate the effect of combining letrozole and GDC-0032 (also known as taselisib) versus letrozole and placebo in postmenopausal women with estrogen…
- Trial name
- NCT02273973
- Testing
- Letrozole, Taselisib
- Where
- 117 sites in United States, Australia and 20 more
- Volunteers
- 334 people
- Sponsor
- Genentech, Inc.
Advanced Breast Cancer
Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer
This is a phase 2, open-label, multicenter, 2-arm study of bosutinib administered in combination with exemestane versus exemestane alone. This is a 2-part study consisting of a safety lead-in phase and randomized phase 2 portion.
- Trial name
- NCT00793546
- Testing
- Bosutinib, exemestane
- Where
- 28 sites in United States, Australia and 9 more
- Volunteers
- 42 people
- Sponsor
- Pfizer
Cognitive Impairment, RRSO
IMProving Executive Function Study
This is a double-blind, placebo-controlled, crossover study testing whether Vyvanse (lisdexamfetamine; LDX) improves executive functioning (EF) in 100 postmenopausal women who report onset of EF difficulties after oophorectomy.
- Trial name
- IMPRES (NCT03187353)
- Testing
- Lisdexamfetamine
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Post Menopausal Osteoporosis
A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis
This single arm, open label study will assess the efficacy and safety of and compliance to treatment with Bonviva/Boniva (ibandronate) in biphosphonate-naïve patients with post-menopausal osteoporosis.
- Trial name
- NCT01290094
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 2 sites in Bosnia and Herzegovina
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Pharmacokinetics
Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects
The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine SR on the pharmacokinetics of Tamoxifen and endoxifen when coadministered to healthy post-menopausal female subjects.
- Trial name
- NCT01189500
- Testing
- Tamoxifen, Tamoxifen and Desvenlafaxine Succinate Sustained Release
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pfizer
Osteoporosis
Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy
A randomized, open label study to assess the safety and effectiveness of Denosumab, administered every 6 months and Actonel ® (Risedronate), administered monthly in post menopausal women transitioned from weekly or daily…
- Trial name
- NCT00919711
- Testing
- Actonel®, Denosumab
- Volunteers
- 870 people
- Sponsor
- Amgen
Breast Cancer
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
This trial is a Phase 2 neoadjuvant study evaluating ARV-471 or anastrozole in post-menopausal women with estrogen receptor positive/ human epidermal growth factor receptor 2 (ER+/HER2)- localized breast cancer.
- Trial name
- NCT05549505
- Testing
- ARV-471, Anastrozole, Surgical resection of breast tumor
- Where
- 49 sites in United States, Georgia and 2 more
- Volunteers
- 152 people
- Sponsor
- Arvinas Inc.
Breast Cancer Female
Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
A short pre-surgical non-therapeutic trial involving postmenopausal women with newly diagnosed eR+, HeR2-negative operable breast cancers.
- Trial name
- NCT03747042
- Testing
- Letrozole
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of Texas Southwestern Medical Center
Postmenopause
Endometrial Safety Study
The study is designed to investigate the safety of the investigational product for the lining of the uterus (endometrium).
- Trial name
- NCT00522873
- Testing
- 0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella)
- Where
- 59 sites in United States, Argentina and 6 more
- Volunteers
- 662 people
- Sponsor
- Bayer
Postmenopausal Women
Effect of Beetroot Juice on Blood Pressure Regulation in Post Menopausal Women
In this study the investigators will test the hypothesis that acute consumption of inorganic nitrate (supplied in concentrated beetroot juice) reduces artery stiffness and resting blood pressure, and lessens the rise in blood…
- Trial name
- NCT03380000
- Testing
- Beetroot juice
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Penn State University
Postmenopausal Osteoporosis
A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)
This 2 arm study will assess the impact of bone marker feedback (BMF), using serum carboxy-terminal collagen crosslinks (CTX) and communication of results at 3 months, on adherence to once monthly ibandronate (150 milligrams [mg]…
- Trial name
- NCT00545363
- Testing
- Ibandronate
- Where
- 52 sites in Hungary, Latvia and 5 more
- Volunteers
- 716 people
- Sponsor
- Hoffmann-La Roche